Coriolis Pharma
Coriolis Pharma is a global contract research and development organization specializing in biologics, including gene and cell therapies, vaccines, and advanced therapy medicinal products. Founded as a spinout from Ludwig-Maximilians University in Munich, the company provides comprehensive support for drug product development, analytical services, and manufacturing across all phases of biopharmaceutical development. The company focuses on formulation development, lyophilization technologies, and analytics for biologics such as proteins, peptides, nucleic acids, and viral vectors. Coriolis Pharma operates facilities with biosafety level 2 certification, allowing it to work with sensitive biologics. Its services include formulation optimization, method development, and non-GMP manufacturing, as well as GMP process development for commercial-scale production. With a recent expansion into the U.S. market, Coriolis Pharma aims to enhance support for North American clients and facilitate transitions from preclinical to clinical stages.
Work at Coriolis Pharma in HR or recruiting? Claim this page
Headcount trend
Coriolis Pharma went from 3 employees in Apr 2023 to 5 in Mar 2025. Oct 2024 to Mar 2025: 2 people joined, 1 left.
Headcount data through Mar 2025
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Oct 2023 | Funding | – | 2 |
Org structure
Headcount by department
Peer reviews
Worked with someone at Coriolis Pharma?
Anonymous peer reviews on OffTheRecord
Similar companies
Coriolis Pharma FAQ
How many employees does Coriolis Pharma have?
Coriolis Pharma has about 5 employees, up 25% over the 3 months to Mar 2025.
What is Coriolis Pharma's revenue per employee?
Coriolis Pharma makes about $2.87M in revenue per employee, based on $14.33M annual revenue and 5 employees.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.